Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pharmaceutical company focused on active pharmaceutical ingredients (APIs) and intermediates, operating multiple manufacturing sites and serving generic drugmakers in regulated and emerging markets; the Viyash platform (Hyderabad-based, founded by ex-Mylan leadership) was built by consolidating several API assets and also offers contract development and manufacturing (CDMO) services.
Viyash Scientific Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Viyash Scientific Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 25.03 crore to 43.69 crore in FY26, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY26 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 4.09 | 0.88 | -1.44 |
| Book value / share (₹) | 71.30 | 30.78 | 28.58 |
| Return on equity | 5.7% | 2.8% | -5.0% |
| Return on capital employed | 11.4% | 8.7% | -0.0% |
| Operating margin | 12.3% | 6.2% | -0.0% |
| Net margin | 6.6% | 2.1% | -2.2% |
| EBITDA | ₹653 Cr | ₹162 Cr | ₹61 Cr |
| Free cash flow | ₹188 Cr | ₹44 Cr | ₹-0 Cr |
| Total debt | ₹436 Cr | ₹446 Cr | ₹451 Cr |
| Debt to equity | 0.14 | 0.58 | 0.63 |
| Interest coverage | 6.0 | 1.6 | 0.0 |
| Current ratio | 2.38 | 1.73 | 1.29 |
| Shares outstanding | 43,68,50,000 | 25,03,00,000 | 24,94,30,000 |
Open the full income statement, balance sheet and cash flow for VIYASH →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.